checkAd
    Startseite > Aktien > Acumen Pharmaceuticals > Nachrichten
    Acumen Pharmaceuticals Aktie
    3,8000
     
    USD
    +2,98 %
    +0,1100 USD
    Letzter Kurs 02:00:00 Nasdaq
    3,7900
     
    USD
    100 STK
    Geldkurs 15.05.24
    3,8000
     
    USD
    400 STK
    Briefkurs 15.05.24
    ISIN: US00509G2093 · WKN: A3CTP6 · SYM: ABOS · USA

    Neueste Nachrichten

    Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
    14.05.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    13.05.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
    08.05.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
    08.05.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
    07.05.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
    16.04.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
    04.04.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
    26.03.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
    21.03.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
    19.03.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
    12.03.24 · globenewswire · Acumen Pharmaceuticals
    Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD 2024 Annual Meeting
    08.03.24 · globenewswire · Acumen Pharmaceuticals